U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Is Slated To Witness Tremendous Growth In Future

U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Summary

The U.S. prostate cancer nuclear medicine diagnostics market size was valued at USD 75.06 million in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 9.2% from 2023 to 2030. The increasing incidence of prostate cancer continues to be one of the major factors driving the demand for early and accurate diagnostic solutions. According to the American Society of Clinical Oncology (ASCO), prostate cancer ranks as the second most common cancer among men, following skin cancer. In 2023 alone, an estimated 288,300 men in the United States are expected to receive a prostate cancer diagnosis. On a global level, approximately 1,414,259 individuals were diagnosed with prostate cancer in 2020, making it the fourth most frequently diagnosed type of cancer worldwide. Around 60% of these cases occur in individuals aged 65 years or older, with the average age of diagnosis at 66. The disease remains rare in individuals under 40. Notably, racial disparities exist, as black men in the United States face a 70% higher risk of being diagnosed with prostate cancer compared to white men.

Ongoing research activities aimed at developing novel imaging agents that enhance the precision and efficiency of prostate cancer detection are further fueling the growth of nuclear medicine diagnostics. Several studies are being carried out to introduce innovative agents for PET imaging that can surpass the capabilities of existing ones. For example, in March 2018, researchers in Italy introduced Copper-64 Chloride (64CuCl2), a promising PET imaging agent, through a study published in The Journal of Nuclear Medicine. The findings indicated that this new imaging agent provided a higher detection rate compared to Fluorine-18-Choline (18F-choline), underscoring its potential as a superior alternative for prostate cancer diagnosis.

Key Market Trends & Insights

• Based on type, the market is segmented into Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET), both of which are widely applied in radiopharmaceutical diagnostic procedures. The adoption of these techniques is driven by factors such as affordability, ease of handling, compatibility of radioisotope half-life, and the broad scope of clinical applications. Together, these advantages have significantly strengthened the role of nuclear imaging in identifying prostate cancer at earlier and more treatable stages.
• The SPECT segment dominated the market, accounting for a 60.75% revenue share in 2022. This growth is primarily attributed to the lower cost of scans compared to PET and the ability to utilize radioisotopes that are easier to source and possess a longer shelf life. Furthermore, the increasing number of clinical studies involving SPECT radiopharmaceuticals to support early diagnosis of prostate cancer is expected to accelerate the expansion of the U.S. market over the forecast period.
• The PET diagnostics market is further segmented by product type into F-18 and SR-82/RB-82. Among these, F-18 held the largest share, accounting for 74.23% of revenue in 2022. Its wide adoption is due to its favorable bio-distribution characteristics and relatively low urinary excretion, which enhances diagnostic accuracy.
• The SR-82/RB-82 segment, on the other hand, is projected to grow at the fastest pace, with a CAGR of 9.9% from 2023 to 2030. This growth is supported by rising demand for PET scans in both diagnosis and staging of prostate cancer, increasing awareness of the clinical benefits of PET imaging, and technological advancements in PET/CT scanners. These new-generation scanners provide improved efficiency, higher resolution, and greater ease of use, which further encourage the adoption of SR-82/RB-82-based imaging in clinical practice.

Order a free sample PDF of the U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2022 Market Size: USD 75.06 million
• 2030 Projected Market Size: USD 153.97 million
• CAGR (2023- 2030): 9.2%

Key Companies & Market Share Insights

Key players in the market are focusing on adopting growth strategies, such as mergers and acquisitions, developing existing devices, promotional events, and technological advancements. For instance, United Imaging Healthcare launched the uMI 510 PET/CT Scanner, a high-resolution scanner with 110,592 LYSO crystals. This makes it one of the most sensitive PET/CT scanners available. The uMI 510 PET/CT Scanner is also more efficient than previous PET/CT scanners, which means it can scan patients faster and with less radiation exposure.

Key Players

• Blue Earth Diagnostics
• Siemens Healthcare Private Limited
• Cardinal Health
• CURIUM PHARMA
• Lantheus
• Jubilant Draximage Radiopharmacies, Inc.
• NCM-USA LLC
• Telix Pharmaceuticals Limited
• ARICEUM THERAPEUTICS
• Novartis AG
• Life Molecular Imaging

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. prostate cancer nuclear medicine diagnostics market is poised for steady growth, supported by increasing prostate cancer incidence, rising demand for advanced imaging modalities, and ongoing innovation in radiopharmaceuticals. While SPECT continues to hold the majority share due to cost-effectiveness, PET-based diagnostics are gaining significant momentum, driven by improved imaging agents such as F-18 and SR-82/RB-82. The emphasis on early detection, coupled with racial and age-related prevalence patterns, highlights the critical need for accurate diagnostics. With research advancements and technology integration, the market is expected to witness transformative progress, offering better outcomes for patients and significant opportunities for industry stakeholders.